Ontology highlight
ABSTRACT: Purpose
Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic diseases. This study describes changes in use, technique, and survival in a population-based cohort.Patients and methods
The study included 38,060 patients with hematologic malignancies or disorders who underwent first alloHCT in a US or Canadian center from 1994 to 2005 and were reported to the Center for International Blood and Marrow Transplant Research.Results
AlloHCT as treatment for acute lymphoblastic (ALL) and myeloid leukemias (AML), myelodysplastic syndrome (MDS), and Hodgkin and non-Hodgkin lymphomas increased by 45%, from 2,520 to 3,668 patients annually. From 1994 to 2005, use of both peripheral (7% to 63%) [corrected] and cord blood increased (2% to 10%), whereas use of marrow decreased (90% to 27%). Despite a median age increase from 33 to 40 years and 165% [corrected] increase in unrelated donors for alloHCT, overall survival (OS) at day 100 significantly improved for patients with AML in first complete remission after myeloablative sibling alloHCT (85% to 94%; P < .001) and unrelated alloHCT (63% to 86%; P < .001); 1-year OS improved among those undergoing unrelated alloHCT (48% to 63%; P = .003) but not among those undergoing sibling alloHCT. Similar results were seen for ALL and MDS. Day-100 OS after cord blood alloHCT improved significantly from 60% to 78% (P < .001) for AML, ALL, MDS, and chronic myeloid leukemia. Use of reduced-intensity regimens increased, yielding OS rates similar to those of myeloablative regimens.Conclusion
Survival for those undergoing alloHCT has significantly improved over time. However, new approaches are needed to further improve 1-year OS.
SUBMITTER: Hahn T
PROVIDER: S-EPMC3691359 | biostudies-literature | 2013 Jul
REPOSITORIES: biostudies-literature
Hahn Theresa T McCarthy Philip L PL Hassebroek Anna A Bredeson Christopher C Gajewski James L JL Hale Gregory A GA Isola Luis M LM Lazarus Hillard M HM Lee Stephanie J SJ Lemaistre Charles F CF Loberiza Fausto F Maziarz Richard T RT Rizzo J Douglas JD Joffe Steven S Parsons Susan S Majhail Navneet S NS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20130528 19
<h4>Purpose</h4>Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic diseases. This study describes changes in use, technique, and survival in a population-based cohort.<h4>Patients and methods</h4>The study included 38,060 patients with hematologic malignancies or disorders who underwent first alloHCT in a US or Canadian center from 1994 to 2005 and were reported to the Center for International Blood ...[more]